Trial Profile
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary) ; Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms ASCEND-BP
- Sponsors GlaxoSmithKline; GSK
- 20 Nov 2020 Status changed from recruiting to completed.
- 21 May 2020 Planned End Date changed from 31 Jul 2020 to 16 Jul 2020.
- 21 May 2020 Planned primary completion date changed from 31 Jul 2020 to 16 Jul 2020.